Key Takeaways
- 42% YoY revenue surge, margin steady: Revenue jumped 42% YoY in Q3 while EBITDA margin held at 15.8%, as the Jammu facility neared EBITDA break-even and the ex-Jammu business delivered ~19% margins.
- Jammu ramp is the central story: Revenue from the new facility rose from ~₹60 crores in Q2 to ~₹89 crores in Q3, with 14 of 15 target clients now validated or in the pipeline.
- Branded generics exploded 79% YoY: Aggressive geographic expansion and a broader portfolio drove the surge, pushing the export mix to 35% of revenue from ~25-27% a year ago.
- Management set a 20%+ FY27 growth target: The target is for the overall entity, with Jammu alone capable of powering 20%+ growth for the next 2-3 years.
- What to watch next quarter: Whether Jammu reaches PAT break-even on schedule, the pace of client commercialisation from the 14 validated accounts, and any concrete detail on the post-FY28 growth strategy management is now working on.
Jammu Facility: The Growth Engine
- Revenue trajectory: Jammu revenue climbed from ~₹60 crores in Q2 to ~₹89 crores in Q3, with full-year FY26 guidance maintained at ₹270-280 crores and a chance to slightly overpass that.
- Profitability timeline: The facility is nearing EBITDA break-even; PAT break-even may take certain quarters, but management is confident of a positive contribution at both EBITDA and PAT level in the next year.
- Client validation nearly complete: 14 out of 15 clients have either validated, visited, completed quality audits, started business, or are in the pipeline to start this quarter or next.
- Certification milestones: PIC/S certification (via SMDC Ukraine) approved for all Jammu blocks, adding to the facility's regulatory credibility with global CDMO partners.
- Growth runway: Jammu alone can deliver 20%+ growth on the overall business basket for the next 2-3 years, making it the primary engine until at least FY28-29.
Lokesh Bhasin: "it is nearing the break-even at EBITDA level. And of course, at break-even, reaching at a PAT, the break-even may take certain quarters. But we are very much sure that in the next year... we are very much looking ahead to get a positive contribution from Jammu facility from both EBITDA as well as PAT level."
Segment Performance
- CDMO momentum: CDMO revenue grew 29% YoY, driven by deeper partnerships with existing clients and wins from new ones, with API price stabilisation providing a supportive backdrop.
- Branded generics breakout: 79% YoY growth came from aggressive geographic expansion both domestically and internationally, a broader portfolio of high-demand products, and agile go-to-market execution.
- Export mix shift: Exports formed 35% of Q3 FY26 revenue versus ~25-27% in Q3 FY25, with management targeting a long-term fair contribution of 35:65 export-to-domestic, give or take 2-5%.
- Sharon contribution: The acquired entity has been a good part of overall growth since acquisition, contributing well on both top line and bottom line.
- Volume vs mix: YoY volume growth was 6-10%; QoQ volume was not much changed, meaning the bulk of growth came from a shift in product and sales mix toward higher-value offerings.
Margin Architecture
- Headline stability: EBITDA margin held at 15.8% for Q3 and 15.5% for 9M, reflecting disciplined cost management even as the Jammu facility still operates below full contribution.
- Ex-Jammu strength: With Jammu at near break-even, the ex-Jammu business delivered an EBITDA margin of ~19%, per an analyst's math, driven by better price realisation, API support, exports, and trade-generic contribution.
- Operational leverage at work: Constant costs like electricity and workmen stayed fixed while performance was optimised, producing substantial ex-Jammu margin improvement.
- API margin pass-through: The business is structured so that margins are generally protected whether API prices rise or fall, because pricing is linked to API cost.
- Future margin outlook: Management aims to maintain the margin profile at 15% (+/- 2%). If Jammu starts contributing, near-term margins should improve, until the next growth strategy with a P&L-negative impact is taken on board.
Vinay Lohariwala: "What happened is that Jammu is now not contributing. In future also we can have some growth engines that is putting a negative on the P&L. So, businesses cannot be set silently and we need to focus continuously on the future growth also."
API & Input Cost Dynamics
- Cephalosporin pricing: Prices have been either stable or slightly increased over the last 4-5 months, a tailwind after earlier volatility.
- YoY vs QoQ picture: Year-on-year, API prices are still negative, but quarter-on-quarter there is much more stabilisation, and the company's outlook always assumes constant API pricing.
- Uncertainty lingers: While Q2-to-Q3 pricing was in stable territory, management cautioned that any prediction about the future remains uncertain.
The Post-Jammu Growth Question
- Beyond FY28-29: Management is actively working on strategies for growth beyond the Jammu ramp-up horizon, acknowledging that Jammu covers the next 2-3 years but a new engine will be needed thereafter.
- No detail yet: The company will inform the market when those strategies are finalised, leaving an open question on what form the next investment cycle takes and what P&L drag it might carry.
Vinay Lohariwala: "Jammu ramping up is the one part that we have already covered that 20% plus growth on overall business. Jammu can give us the next two to three years 20% plus growth, the overall basket could be there. But we need to think beyond 2 to 3 year time horizon, how the future after '28-'29 from where the growth will come."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Overall revenue growth | 20%+ YoY at entity/group level | FY27 |
| Jammu facility revenue | ₹270-280 crores, may slightly overpass | FY26 |
| Jammu profitability | Positive contribution at both EBITDA and PAT level | Next year (FY27) |
| Jammu-driven growth runway | 20%+ growth on overall basket from Jammu alone | Next 2-3 years |
| EBITDA margin profile | Maintain at 15% (+/- 2%) | Ongoing |
| Export-to-domestic mix | Long-term fair contribution 35:65 (+/- 2-5%) | Long-term |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹450.3 crores, 42.3% YoY growth |
| 9M FY26 consolidated revenue | ₹1,182.2 crores, 27.3% YoY growth |
| CDMO revenue | ₹298.7 crores, 29% YoY growth from ₹231.6 crores |
| Branded generics revenue | ₹151.6 crores, 79% YoY growth |
| EBITDA | ₹71.1 crores, 39.6% YoY increase from ₹50.9 crores |
| EBITDA margin | 15.8%, steady; 15.5% for 9M FY26 |
| PAT | ₹42.1 crores; ₹102.8 crores for 9M FY26 |
| Ex-Jammu EBITDA margin | 18-19% (per an analyst's math) |
| Export share of revenue | 35% of Q3 FY26 revenue mix, up from 25-27% in Q3 FY25 |
| Jammu facility revenue | ₹89 crores, up from ₹60 crores in Q2 FY26 |
| Jammu facility FY26 revenue guidance | ₹270-280 crores range |
| Volume growth (CDMO, YoY) | 6% to 10% |
| Capacity utilization (Baddi, Dehradun, Taloja) | 55% to 60% |
| Operating cash flow (9M FY26, before working capital changes and tax) | ₹182 crores at group level |
| FY27 overall growth outlook | 20% plus |